Biopharma Layoff Tracker 2024: Industry-Wide Job Cuts Continue
Biopharma, Layoffs, Job Cuts, Industry Tracker, 2024
Biopharma Layoff Tracker 2024: Merck, Rapt, Aslan and More Cut Staff
Biopharma, Layoffs, Merck, Rapt, Aslan, Pharmaceutical Industry, Job Cuts, Restructuring
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Pfizer’s Hemophilia A Gene Therapy Candidate Achieves Phase 3 Success
Pfizer, Hemophilia A, Gene Therapy, Phase 3 Trial, Giroctocogene Fitelparvovec, Bleeding Rate Reduction
Telix Pharmaceuticals Raises $400M in Bond Sale Amid IPO Uncertainty
Telix Pharmaceuticals, Bond Sale, IPO, Radiopharma, Funding
Third Arc Bio Debuts with $165M Funding and Former J&J Executives at the Helm
Third Arc Bio, J&J, biotech, funding, executives, cancer, immune disease
Merck’s Investigational RSV Antibody, Clesrovimab, Meets Primary Safety and Efficacy Endpoints in Phase 2b/3 Trial for Infant Prevention
Merck, RSV, Clesrovimab, Monoclonal Antibody, Infant Prevention, Respiratory Syncytial Virus, Phase 2b/3 Trial
Bluebird Bio’s Fertility Support Program for Gene Therapies Rejected by HHS Inspector General
Bluebird Bio, Gene Therapy, Fertility Support, HHS Inspector General, Zynteglo, Skysona, Anti-Kickback Rules
Fierce Biotech Layoff Tracker 2024: Industry-Wide Job Cuts Continue
Biotech Layoffs, 2024, MEI Pharma, Rapt Therapeutics, Industry Cuts
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial
GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare